Clinical Trials Logo

Filter by:
NCT ID: NCT05910970 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

PREVENT-2
Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

Though hepatic resection and ablation are the curative treatments for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced or unresectable HCC. No study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy is reported.

NCT ID: NCT05910398 Recruiting - Clinical trials for Breast Cancer Invasive

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

CORINNE-PI
Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

NCT ID: NCT05910242 Recruiting - Clinical trials for Essential Hypertension

Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.

NCT ID: NCT05910177 Recruiting - Carcinoma Clinical Trials

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

NCT ID: NCT05910125 Not yet recruiting - Ischemic Stroke Clinical Trials

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke

AGREE
Start date: July 2023
Phase: Phase 4
Study type: Interventional

An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset. Eligible participants would be randomly assigned to the thrombolysis group (intravenous alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at 90 days.

NCT ID: NCT05909982 Recruiting - Clinical trials for Acute Ischemic Stroke

Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-1b)

PROTECT
Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Ischemic post-conditioning is a neuroprotective strategy attenuating reperfusion injury in animal stroke models. The investigators have conducted a 3 + 3 dose-escalation trial to demonstrate the safety and tolerability of ischemic post-conditioning incrementally for a longer duration of up to 5 min × 4 cycles in stroke patients undergoing mechanical thrombectomy. This study aims to assess the infarct volume after ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy.

NCT ID: NCT05909943 Withdrawn - Clinical trials for Neuromyelitis Optica Spectrum Disorder Relapse

Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

Start date: June 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.

NCT ID: NCT05909904 Recruiting - Clinical trials for Head and Neck Cancer

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT05909696 Enrolling by invitation - Succinylcholine Clinical Trials

Median Effective Dose of Rocuronium for the Prevention of Myofibrillation Caused by the Injection of Succinylcholine

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Succinylcholine is an important component of rapid sequential induction of general anesthesia because of its rapid onset and short duration of action. However, myofibrillation is a common complication after succinylcholine injection and may lead to persistent postoperative myalgia, increased intraocular, intragastric and intracranial pressure in patients. Increased risk of peri-induction and postoperative patient discomfort. The effectiveness of rocuronium bromide pretreatment in reducing succinylcholine-induced myalgias has been demonstrated in several recent studies. However, the half effective amount of rocuronium pretreatment for small doses is not well known. Therefore, this study applied the Dixon sequential method to investigate the ED50 of preemptive intravenous rocuronium bromide for the prevention of succinylcholine-induced myofibrillation and to investigate the effect of age factor on the ED50 of rocuronium bromide for the prevention of succinylcholine-induced myofibrillation to provide a reference for the rational clinical selection of rocuronium bromide dose.

NCT ID: NCT05909540 Enrolling by invitation - Clinical trials for Basilar Invagination

A Prospective Study of Natural History and Clinical Outcomes for Basilar Invagination

Start date: February 6, 2022
Phase:
Study type: Observational

A Prospective Study of Natural History and Clinical Outcomes for Basilar Invagination